Incidence of Antimicrobial-Associated Acute Kidney Injury in Children: A Structured Review
In conclusion, antimicrobial-associated AKI is reported to occur frequently in children, but the rates of AKI varies widely across studies and drugs. Most published studies examined hospitalized patients and heterogeneity in study populations and in author definitions of AKI are barriers to a comparison of nephrotoxicity risk among antimicrobials in children.PMID:38093147 | DOI:10.1007/s40272-023-00607-5 (Source: Paediatric Drugs)
Source: Paediatric Drugs - December 13, 2023 Category: Pediatrics Authors: Torsten Joerger Molly Hayes Connor Stinson Ibram Mikhail Kevin J Downes Source Type: research
Incidence of Antimicrobial-Associated Acute Kidney Injury in Children: A Structured Review
In conclusion, antimicrobial-associated AKI is reported to occur frequently in children, but the rates of AKI varies widely across studies and drugs. Most published studies examined hospitalized patients and heterogeneity in study populations and in author definitions of AKI are barriers to a comparison of nephrotoxicity risk among antimicrobials in children.PMID:38093147 | DOI:10.1007/s40272-023-00607-5 (Source: Paediatric Drugs)
Source: Paediatric Drugs - December 13, 2023 Category: Pediatrics Authors: Torsten Joerger Molly Hayes Connor Stinson Ibram Mikhail Kevin J Downes Source Type: research
Incidence of Antimicrobial-Associated Acute Kidney Injury in Children: A Structured Review
In conclusion, antimicrobial-associated AKI is reported to occur frequently in children, but the rates of AKI varies widely across studies and drugs. Most published studies examined hospitalized patients and heterogeneity in study populations and in author definitions of AKI are barriers to a comparison of nephrotoxicity risk among antimicrobials in children.PMID:38093147 | DOI:10.1007/s40272-023-00607-5 (Source: Paediatric Drugs)
Source: Paediatric Drugs - December 13, 2023 Category: Pediatrics Authors: Torsten Joerger Molly Hayes Connor Stinson Ibram Mikhail Kevin J Downes Source Type: research
Incidence of Antimicrobial-Associated Acute Kidney Injury in Children: A Structured Review
In conclusion, antimicrobial-associated AKI is reported to occur frequently in children, but the rates of AKI varies widely across studies and drugs. Most published studies examined hospitalized patients and heterogeneity in study populations and in author definitions of AKI are barriers to a comparison of nephrotoxicity risk among antimicrobials in children.PMID:38093147 | DOI:10.1007/s40272-023-00607-5 (Source: Paediatric Drugs)
Source: Paediatric Drugs - December 13, 2023 Category: Pediatrics Authors: Torsten Joerger Molly Hayes Connor Stinson Ibram Mikhail Kevin J Downes Source Type: research
Bosutinib: Pediatric First Approval
This article summarizes the milestones in the development of bosutinib leading to this first pediatric approval.PMID:38060099 | DOI:10.1007/s40272-023-00608-4 (Source: Paediatric Drugs)
Source: Paediatric Drugs - December 7, 2023 Category: Pediatrics Authors: Sheridan M Hoy Source Type: research
Bosutinib: Pediatric First Approval
This article summarizes the milestones in the development of bosutinib leading to this first pediatric approval.PMID:38060099 | DOI:10.1007/s40272-023-00608-4 (Source: Paediatric Drugs)
Source: Paediatric Drugs - December 7, 2023 Category: Pediatrics Authors: Sheridan M Hoy Source Type: research
Bosutinib: Pediatric First Approval
This article summarizes the milestones in the development of bosutinib leading to this first pediatric approval.PMID:38060099 | DOI:10.1007/s40272-023-00608-4 (Source: Paediatric Drugs)
Source: Paediatric Drugs - December 7, 2023 Category: Pediatrics Authors: Sheridan M Hoy Source Type: research
Bosutinib: Pediatric First Approval
This article summarizes the milestones in the development of bosutinib leading to this first pediatric approval.PMID:38060099 | DOI:10.1007/s40272-023-00608-4 (Source: Paediatric Drugs)
Source: Paediatric Drugs - December 7, 2023 Category: Pediatrics Authors: Sheridan M Hoy Source Type: research
Bosutinib: Pediatric First Approval
This article summarizes the milestones in the development of bosutinib leading to this first pediatric approval.PMID:38060099 | DOI:10.1007/s40272-023-00608-4 (Source: Paediatric Drugs)
Source: Paediatric Drugs - December 7, 2023 Category: Pediatrics Authors: Sheridan M Hoy Source Type: research
Bosutinib: Pediatric First Approval
This article summarizes the milestones in the development of bosutinib leading to this first pediatric approval.PMID:38060099 | DOI:10.1007/s40272-023-00608-4 (Source: Paediatric Drugs)
Source: Paediatric Drugs - December 7, 2023 Category: Pediatrics Authors: Sheridan M Hoy Source Type: research
Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date
Paediatr Drugs. 2023 Nov 30. doi: 10.1007/s40272-023-00606-6. Online ahead of print.ABSTRACTRespiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in children, and is associated with long-term pulmonary sequelae for up to 30 years after infection. The mainstay of RSV management is supportive therapy such as supplemental oxygen. Palivizumab (Synagis™-AstraZeneca), a monoclonal antibody targeting the RSV F protein site II, has been licensed for the prevention of RSV in high-risk groups since 1998. There has been recent promising progress in preventative strategies that includ...
Source: Paediatric Drugs - November 30, 2023 Category: Pediatrics Authors: Charl Verwey Ziyaad Dangor Shabir A Madhi Source Type: research
Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date
Paediatr Drugs. 2023 Nov 30. doi: 10.1007/s40272-023-00606-6. Online ahead of print.ABSTRACTRespiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in children, and is associated with long-term pulmonary sequelae for up to 30 years after infection. The mainstay of RSV management is supportive therapy such as supplemental oxygen. Palivizumab (Synagis™-AstraZeneca), a monoclonal antibody targeting the RSV F protein site II, has been licensed for the prevention of RSV in high-risk groups since 1998. There has been recent promising progress in preventative strategies that includ...
Source: Paediatric Drugs - November 30, 2023 Category: Pediatrics Authors: Charl Verwey Ziyaad Dangor Shabir A Madhi Source Type: research
Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date
Paediatr Drugs. 2023 Nov 30. doi: 10.1007/s40272-023-00606-6. Online ahead of print.ABSTRACTRespiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in children, and is associated with long-term pulmonary sequelae for up to 30 years after infection. The mainstay of RSV management is supportive therapy such as supplemental oxygen. Palivizumab (Synagis™-AstraZeneca), a monoclonal antibody targeting the RSV F protein site II, has been licensed for the prevention of RSV in high-risk groups since 1998. There has been recent promising progress in preventative strategies that includ...
Source: Paediatric Drugs - November 30, 2023 Category: Pediatrics Authors: Charl Verwey Ziyaad Dangor Shabir A Madhi Source Type: research
Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date
Paediatr Drugs. 2023 Nov 30. doi: 10.1007/s40272-023-00606-6. Online ahead of print.ABSTRACTRespiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in children, and is associated with long-term pulmonary sequelae for up to 30 years after infection. The mainstay of RSV management is supportive therapy such as supplemental oxygen. Palivizumab (Synagis™-AstraZeneca), a monoclonal antibody targeting the RSV F protein site II, has been licensed for the prevention of RSV in high-risk groups since 1998. There has been recent promising progress in preventative strategies that includ...
Source: Paediatric Drugs - November 30, 2023 Category: Pediatrics Authors: Charl Verwey Ziyaad Dangor Shabir A Madhi Source Type: research
Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date
Paediatr Drugs. 2023 Nov 30. doi: 10.1007/s40272-023-00606-6. Online ahead of print.ABSTRACTRespiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in children, and is associated with long-term pulmonary sequelae for up to 30 years after infection. The mainstay of RSV management is supportive therapy such as supplemental oxygen. Palivizumab (Synagis™-AstraZeneca), a monoclonal antibody targeting the RSV F protein site II, has been licensed for the prevention of RSV in high-risk groups since 1998. There has been recent promising progress in preventative strategies that includ...
Source: Paediatric Drugs - November 30, 2023 Category: Pediatrics Authors: Charl Verwey Ziyaad Dangor Shabir A Madhi Source Type: research
